Vaxcyte’s (PCVX) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Vaxcyte (NASDAQ:PCVX) in a research report report published on Wednesday, Benzinga reports.

PCVX has been the subject of several other reports. Mizuho boosted their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Needham & Company LLC restated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday. Leerink Partners raised their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. BTIG Research boosted their price target on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Bank of America lifted their target price on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Trading Down 3.2 %

Shares of PCVX opened at $104.07 on Wednesday. Vaxcyte has a 12-month low of $46.16 and a 12-month high of $121.06. The firm has a market cap of $11.62 billion, a P/E ratio of -22.62 and a beta of 1.01. The company’s 50-day moving average price is $110.06 and its 200 day moving average price is $86.69.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the company posted ($0.91) earnings per share. Equities research analysts forecast that Vaxcyte will post -4.33 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares in the company, valued at $21,968,226. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Andrew Guggenhime sold 42,000 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00. Following the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,429,294.37. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $21,968,226. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 115,098 shares of company stock valued at $12,394,473. 3.10% of the stock is owned by company insiders.

Institutional Trading of Vaxcyte

Institutional investors have recently made changes to their positions in the stock. Riverview Trust Co acquired a new position in shares of Vaxcyte in the 3rd quarter valued at about $27,000. Blue Trust Inc. boosted its position in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after buying an additional 93 shares during the last quarter. Fifth Third Bancorp acquired a new stake in shares of Vaxcyte during the second quarter valued at about $35,000. Fidelis Capital Partners LLC purchased a new stake in shares of Vaxcyte during the first quarter worth about $37,000. Finally, J.Safra Asset Management Corp increased its position in shares of Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after acquiring an additional 526 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.